Bon Natural Life Limited (Nasdaq: BON) (“BON” or the “Company”), a leading bio-ingredient solution provider in the natural, health and personal care industry, announced on Thursday, March 20 that a game-changing patent for a natural postbiotic ingredient designed to regulate blood sugar was gearing up for release.

Yongwei Hu, CEO & Chairman of BON, said “Backed by a robust IP strategy, BON is aggressively pursuing global patent protection. Over the next two years, we plan to lock down approvals across top markets, safeguarding our innovation while positioning ourselves for long-term dominance in the fast-growing metabolic health space. This strategic move not only shields the technology but also primes the business for scalable revenue growth and investor appeal.”

As China pushes its Healthy China 2030 agenda, the health industry is riding a sustained growth wave. According to iiMedia Data, a local authoritative third-party data monitoring institution, the market size of China’s health food products industry in 2023 exceeded 328 billion RMB ($45.5 billion), and is expected to reach 423.7 billion RMB ($58.8 billion) by 2027. Among them, vitamins and dietary supplements (VDS) account for over half of the total market. While China’s VDS spending per capita remains 22% of the U.S. levels, analysts project accelerated demand driven by aging demographics and preventive healthcare trends.

BON is positioning itself at the forefront of this fastest-growing industry. A strategic partnership built on March 9 with China’s agricultural giant Sanzhuliang Group Co., Ltd. signals BON’s ambition to bridge farming and biotech. The collaboration, facilitated by the Listed Companies Division of Commercial Culture Association of China, will focus on biotech innovation, functional food R&D, smart agriculture, industry standards, and more. An expert workstation under the Division was launched at BON’s headquarters to advance digital transformation and promote traditional Chinese medicine globally.

The Company’s recent stock surge underscores investor confidence in its leadership in China’s trillion-dollar functional food market. On Friday, March 14, BON stock skyrocketed over 300%, triggering multiple trading halts. Days later, BON priced a best efforts offering of $12 million, before deducting placement agent fees and other estimated expenses payable by the Company. BON intends to use the net proceeds from this offering for R&D, product expansion, global marketing and other corporate purposes.

As one of the few suppliers of stachyose, an extract from stachy affinis and also a prebiotic that can promote human intestinal health, BON has built an international footprint with products sold across Asia, the U.S., and the EU. Its portfolio includes stachyose, apple polyphenols, broccoli extracts, and proprietary formulations like probiotic powder drinks and micro-eco repair shampoos.

About Bon Natural Life Limited (“BON”)

BON is a Cayman Islands company engaged in the business of natural, health, and personal care industries. For more information, please visit the Company’s website at http://www.bnlus.com.

文章來源：美聯社https://www.universalpressrelease.com/?pr=bon-announces-revolutionary-postbiotic-blood-sugar-solution-nears-patent-launch